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SUMMARY 27 
In autumn 2014, enterovirus D68 (EV-D68) cases presenting with severe respiratory 28 
or neurological disease were described in countries worldwide. To describe the 29 
epidemiology and virological characteristics of EV-D68 in England, we collected 30 
clinical information on laboratory-confirmed EV-D68 cases detected in secondary 31 
care (hospitals), between September 2014 and January 2015. In primary care (general 32 
practitioners), respiratory swabs collected (September 2013-January 2015) from 33 
patients presenting with influenza-like-illness were tested for EV-D68. In secondary 34 
care 55 EV-D68 cases were detected. Among those, 45 cases had clinical information 35 
available and 89% (40/45) presented with severe respiratory symptoms. Detection of 36 
EV-D68 among patients in primary care increased from 0.4% (4/1074; 95%CI: 0.1-37 
1.0) (September 2013-January 2014) to 0.8% (11/1359; 95%CI: 0.4-1.5) (September-38 
2014 to January-2015). Characterization of EV-D68 strains circulating in England 39 
since 2012 and up to winter 2014/2015 indicated that those strains were genetically 40 
similar to those detected in 2014 in USA. We recommend reinforcing enterovirus 41 
surveillance through screening respiratory samples of suspected cases.  42 
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 49 
BACKGROUND 50 
The Enterovirus genus (family Picornaviridae) includes twelve species (A-J) of 51 
which four (A-D) are associated with disease in humans; each of these species 52 
encompasses multiple types. Enterovirus infection can be associated with a broad 53 
range of clinical presentations, including meningitis, encephalitis, hand, foot and 54 
mouth disease (HFMD), respiratory illness, and more rarely, neurological symptoms. 55 
Multiple enterovirus types co-circulate, and some types are known to emerge 56 
occasionally in a population to cause outbreaks or clusters of cases of acute 57 
neurological disease [1, 2]. Increasing recognition of the disease burden associated 58 
with enterovirus infections, and the description of ‘re-emerging’ enteroviruses such as 59 
EV-C99, EV-C104, EV-D70, EV-A71 [3, 4], provide evidence that enteroviruses have 60 
rapidly evolving genomes, are ubiquitous worldwide, spread rapidly via faecal-oral 61 
and environmental routes, but also via respiratory transmission, and have the ability to 62 
cause severe disease. Enterovirus D68 (EV-D68) is one of five enterovirus types 63 
assigned to Enterovirus species D. The virus was first described in 1962, isolated from 64 
children with pneumonia and bronchitis [5]; in 2002 a human rhinovirus 87 was 65 
reclassified as EV-D68, based on phylogenetic analysis [6]. In countries with 66 
enterovirus established surveillance EV-D68 has been detected sporadically in cases 67 
of acute respiratory illness, particularly in children, and occasionally was associated 68 
with acute neurological disease and other severe outcomes [7, 8].  69 
In autumn 2014, the United States of America (USA) experienced a nationwide 70 
outbreak of EV-D68 associated with severe acute respiratory illness [9].  This 71 
outbreak coincided with an apparent increase in incidence of reported cases of 72 
neurological disease characterized as acute flaccid myelitis (AFM), suggesting that 73 
AFM is a rare yet severe clinical manifestation of EV-D68 infection [10-12].  74 
In 2014, following the USA outbreak, EV-D68 was detected in European countries 75 
[13]. In Norway, EV-D68 was detected in 11% of 303 paediatric nasopharyngeal 76 
samples collected from children hospitalized with acute respiratory infection. EV-D68 77 
was associated with acute flaccid paralysis in one child [14]. In the Netherlands, 1% 78 
(18/1896) of respiratory samples taken from patients with respiratory symptoms tested 79 
positive for EV-D68 [15]. Phylogenetic analysis showed that strains detected in the 80 
Netherlands were genetically similar to those circulating in the USA in 2014 [15].   81 
Public Health England (PHE) has an established national Enterovirus Surveillance 82 
System (ESS), with emphasis on further investigation of enterovirus-positive cases 83 
presenting with acute neurological symptoms as part of enhanced poliovirus 84 
surveillance [16]. Following reports of the emergence of EV-D68 in USA, PHE issued 85 
guidance on October 2014 that EV-D68 should be considered as a possible cause of 86 
disease, particularly in children presenting with severe acute respiratory infections 87 
and/or unexplained neurological symptoms, and where standard respiratory virus 88 
screens were negative, or if a combined rhinovirus/enterovirus positive result was 89 
initially detected.   90 
This study aimed to quantify the circulation of EV-D68 in England in primary and 91 
secondary care before and after the identification of EV-D68 in North America in 92 
autumn 2014.  Our objectives were i) to determine whether there was an increase in 93 
number of cases between autumn/winter 2013-2014 and autumn/winter 2014-2015, 94 
and ii) to describe the clinical presentation and phylogenetic characteristics of this 95 
virus, including severity in England in the autumn/winter 2014-2015. 96 
METHODS 97 
A confirmed case was any patient presenting to primary or secondary care with a 98 
specimen positive for EV-D68 detected initially by one-step real-time reverse 99 
transcription PCR (rRT-PCR) [15] . Cases investigated in this study were identified 100 
from two surveillance sources. 101 
1. Secondary care (clinical presentations) 102 
As part of the ESS, samples (including stool, cerebrospinal fluid (CSF) and 103 
respiratory samples) from individuals who presented to hospitals with acute 104 
neurological syndromes and in whom an enterovirus is detected are sent for 105 
enterovirus typing. This typing is carried out at the Virus Reference Department, PHE, 106 
Colindale. From November 2014, referrals to the ESS were enhanced, to include 107 
enterovirus-positive paediatric cases with acute respiratory symptoms. The 108 
Respiratory Diseases Department of the PHE Centre for Infectious Disease 109 
Surveillance and Control (CIDSC) coordinated the epidemiological investigation of 110 
each confirmed case. 111 
Using a standardized questionnaire the treating clinicians collected information on all 112 
confirmed EV-D68 cases from October 2014 to February 2015.  The  information 113 
gathered included: patient characteristics, clinical presentation (including details on 114 
the neurological and respiratory presentations), testing performed (including all 115 
pathogens detected and type of samples) and disease outcome.   116 
2. Primary care (EV-D68 circulation) 117 
To estimate the rate of circulation of EV-D68 in the community, we tested  respiratory 118 
samples from the general practitioner (GP) influenza sentinel surveillance system. 119 
Patients presenting with acute febrile respiratory illness considered by their GP to be 120 
influenza-like-illness (ILI) had nasopharyngeal virology specimens sent to PHE, as 121 
part of the Royal College of General Practitioners Research and Surveillance Centre 122 
(RCGP RSC) influenza sentinel surveillance weekly returns service. These specimens 123 
were tested for EV-D68. This service, run by RCGP RSC since 1957, provides 124 
clinical surveillance data from a sentinel network of over 100 general practices (GP) 125 
(primary health care centres) together with  virological respiratory specimens, from a 126 
subset of patients presenting with ILI  across England [17]. Each GP sends around 127 
five combined nose and throat swabs per week from patients consulting with ILI, 128 
particularly during the winter season, from around week 40 of one year to around  129 
week 20 of the  next year.  Among the samples received from the RCGP RSC from 130 
week 39-2013 to week 15-2015 (September 2013 to April 2015) only those testing 131 
negative for influenza virus were tested for EV-D68.   132 
Data analysis 133 
Changes in circulation of EV-D68 were estimated by calculating EV-D68 percent 134 
positivity in two periods.  Percent positivity was calculated as number of EV-D68 135 
positive samples divided by total of samples tested for EV-D68 in each period. 136 
Percent positivity in the period week 39-2013 to week 05-2014 (September 2013 to 137 
January 2014) (in 2013 RCGP RSC influenza testing only started in week 39) was 138 
compared to percent positivity in the period week 36-2014 to week 05-2015 139 
(September 2014 to February 2015), using Chi-square test. For primary care samples, 140 
we only looked at percent positivity and demographic characteristics (age and sex) of 141 
cases.  142 
Laboratory detection and characterization 143 
Detection of EV-D68 was performed by rRT-PCR as previously described [15]. 144 
Further characterization of EV-D68 strains was performed by amplification and 145 
partial sequencing of the VP1 coding region using a previously developed in-house 146 
assay (M. Iturriza-Gómara, University of Liverpool, UK). Briefly, primers Ent68F 147 
[5’-GAAGCCATACAAACTCGCAC-3’] and Ent68R [5’-148 
ATTWGCAATGCTCATGTATGG-3’] were used to amplify a ~670nt fragment of 149 
the VP1 coding region. A high fidelity PCR system was used (Expand High Fidelity 150 
PCR Kit, Roche, UK) according to manufacturer’s instruction, with the following 151 
specifications (per reaction): magnesium chloride final concentration 2.5mM, 40pmol 152 
each primer, and 1.75U DNA polymerase. Amplification was performed under the 153 
following conditions: initial denaturation: 95oC, 240 seconds; thermal cycling 95oC, 154 
30 seconds – 42oC, 60 seconds – 72oC, 60 seconds for 40 cycles; final extension: 155 
72oC, 240 seconds.  156 
Sequence analysis was performed using Bionumerics v6.1 (Applied Maths, 157 
Kortijk,Belgium) and phylogenetic and molecular evolutionary analyses were 158 
conducted using MEGA version 6 [18]. 159 
For phylogenetic analysis, we included representatives of EV-D68 strains detected in 160 
the USA in 2014 [19] and 2015 [20], EV-D68 strains detected in England in 2010-161 
2013 as part of national enterovirus surveillance and  enhanced poliovirus surveillance 162 
[21] and representatives of other EV-D68 strains reported globally [22-24]. 163 
 164 
RESULTS  165 
Clinical presentation of EV-D68 in England  166 
From week 42-2014 to week 05-2015 (October 2014 to February 2015), 433 167 
respiratory samples were collected from patients presenting to secondary care in 168 
England.  During this period, 13% (55/433) of these respiratory samples were positive 169 
for EV-D68, compared with 11% (3/26) of EV-D68 positive samples detected in the 170 
same period in the previous year (Figure 1). Sixty-nine percent (38/55) of the EV-D68 171 
cases (October 2014 to February 2015) were in children under 12 years of age; the 172 
median age of cases was 4 years (range 0-71), and there was no difference in the 173 
gender distribution (46% male) (Figure 2).The majority of these EV-D68 positive 174 
specimens were nasopharyngeal aspirates, 44% (24/55),  and nose/throat swabs, 175 
31%(17/55). The remaining 14 were sputum, mouth swabs and tracheal/bronco 176 
alveolar aspirates.  EV-D68 was not detected in any CSF specimen tested (n=562).  177 
Detailed clinical information was available for 82% (45/ 55) EV-D68 cases (Table 1). 178 
None of these cases reported having recently travelled outside of the United Kingdom 179 
(UK). Ninety-one percent (41/45) of the cases presented with acute respiratory 180 
symptoms, one case presented with HFMD, one case had leukaemia (respiratory 181 
symptoms not reported) and two cases presented with acute neurological symptoms. 182 
These cases showing neurological presentations were in children <5 years of age: one 183 
case presented with meningoencephalitis and paucity of limb movements [22]; the 184 
second presented with afebrile seizures and respiratory arrest. These cases were 185 
previously healthy children who required intensive care unit (ICU) treatment and 186 
subsequently recovered; in both cases, EV-D68 was detected in nasopharyngeal 187 
aspirate specimens. Thirty-three percent (13/39) of the cases presented with asthma or 188 
wheezing, 84% (11/13) of them were children under 15 years of age (median age: 2 189 
years) (information for asthma was only collected for 39 patients). Forty-seven 190 
percent (21/45) of the cases were immunocompromised or had an underlying chronic 191 
condition. Eighty-two percent (37/45) of the cases were admitted to hospital, with 192 
27% (12/45) requiring treatment in ICU, all of them children (median age: <1 year) 193 
(Table 1). Two patients in whom EV-D68 was detected died: both were infants with 194 
underlying neurological problems. Information on cause of death was only accessible 195 
for one of them: it was likely due to complications in the underlying neurological 196 
problems. Two other infant cases had never left the hospital since birth. 197 
Estimate of prevalence of EV-D68 in England 198 
A total of 3575 nose/throat swab samples were collected from week 39-2013 to week 199 
15-2015 (September 2013 to April 2015) as part of the RCGP RSC influenza sentinel 200 
surveillance weekly returns service. The median age of the patients providing these 201 
samples was 33 years (range 0-99), 17% of them were children <12 years of age. 202 
Sixty-one percent were female.  203 
EV-D68 was detected in 0.4% (15/3575) of all the community respiratory samples 204 
analysed. Among the cases, the median age was 40 years, (range 5-84 years); nine 205 
(60%) of them were female (Figure 2). Among those 3575 samples, 2433 206 
(1074+1359) had been collected during the two periods of comparison and were 207 
included in the percent positivity analysis.  Positivity in the autumn/winter 2013/14 208 
(week 39-2013 to week 05-2014) was 0.4% (4/1074; 95%CI: 0.1-1.0). Positivity in 209 
the autumn/winter 2014/15 (week 36-2014 to week 05-2015) was 0.8% (11/1359) 210 
(95%CI: 0.4-1.5) (p value=0.17). All primary care (RCGP RSC) EV-D68 positive 211 
samples in 2013 were collected between weeks 40 to 47, while all the community EV-212 
D68 positive samples from 2014 were collected between weeks 49 to 52 (Figure 1). 213 
Phylogenetics 214 
Partial VP1 sequence was obtained from 88% (57/70) of the EV-D68 cases  215 
identified from primary and secondary care in this study (four from community cases 216 
recruited via the RCGP network and 53 from cases referred to the ESS).  217 
Of the 57 EV-D68 sequences detected in this study, 56 clustered with EV-D68 genetic 218 
clades (A and B as described elsewhere [23]): 49 (85%) in clade B and 8 (14%) in 219 
clade A. The remaining 2014 strain clustered with the prototype US/Fermon/1962 220 
strain (Figure 3). 221 
EV-D68 strains detected in England in 2014 and 2015 clustered both with strains 222 
detected in the USA during the same period, and with strains circulating in England 223 
prior to 2014. Among the clade B viruses there were the two sequences found in cases 224 
with neurological presentation. Both of these sequences were highly similar to other 225 
co-circulating viruses from the same period. 226 
Amino acid sequences were highly similar within clades, with most amino acid 227 
differences occurring in the BC and DE loops (data not shown). There were no 228 
specific amino acid changes in either the BC or DE loop, or elsewhere in the regions 229 
of VP1 sequenced that distinguished strains associated with neurovirulence from other 230 
EV-D68 strains detected. 231 
DISCUSSION  232 
We used two established surveillance systems for this study. From the national 233 
enterovirus surveillance system data we described the burden of illness due to EV-234 
D68 and the severity of clinical presentation in England. We used the influenza 235 
sentinel GP surveillance system to look at the changes in EV-D68 circulation in 236 
primary care. Clinical information from the cases identified in the ESS (secondary 237 
care) found that cases with EV-D68 positive samples were mainly presenting with 238 
severe respiratory symptoms in the autumn/early winter 2014-2015. In primary care, 239 
retrospective testing of samples revealed a non-significant increase in circulation of 240 
EV-D68 in autumn/early winter 2014-2015 compared to the same period the previous 241 
year.  242 
Our findings from secondary care suggest that, when detected, EV-D68 is most 243 
frequently associated with respiratory disease, usually in children, and more rarely 244 
with neurological disease. Previous studies presented comparable results [9, 24-27]. 245 
Further, in our study the majority of hospitalized cases presented with severe 246 
respiratory disease and one third of those were admitted to ICU (all of them children) 247 
and required respiratory support. Our results on cases with severe respiratory 248 
presentations, mostly children, associated with EV-D68 infection were comparable to 249 
similar findings in the Netherlands and the USA [15, 27].  We found that 33% of 250 
cases presented with asthma/wheezing compared to the 70% of cases presenting with 251 
these symptoms in the 2014 USA outbreak [27], this difference could be attributable 252 
to the small number of cases for whom we had information on asthma/wheezing.  In 253 
our study, similarly to other studies, almost half of the patients admitted with 254 
respiratory disease were immunosuppressed or had severe underlying conditions [15, 255 
28]. Our findings reinforce the importance of clinicians considering EV-D68 (and 256 
other enteroviruses) as one of the differential diagnoses of severe acute respiratory 257 
illness, particularly in children. 258 
In the only two acute neurological presentations in our study, EV-D68 was not 259 
detected in the CSF of these children and the detection of EV-D68 in the respiratory 260 
samples may have been coincidental. However, both cases were previously healthy 261 
and no other infectious cause was identified for the disease. Therefore we cannot 262 
exclude the possibility of an association between EV-D68 and their severe acute 263 
presentations. Both children made a complete recovery. Severe neurological 264 
presentations associated with EV-D68 in previously healthy children with a preceding 265 
respiratory infection  have been reported in different European countries: in Norway, 266 
two cases (Autumn 2014) [29]; a case in France (September 2014) [30] and two cases 267 
in Wales (UK) (January 2016) [31], EV-D68 was not identified in the CSF in any of 268 
these cases, but rather from upper respiratory tract samples. Similarly, we found that 269 
EV-D68 RNA was detectable in respiratory specimens, but that other sample types 270 
(e.g. CSF or stool) were not sensitive for detection of EV-D68. We were able to 271 
recover infectious EV-D68 virus by inoculation of permissive cell lines with RT-PCR-272 
positive respiratory specimens, but not other specimen types. This highlights the 273 
importance of collecting all clinically relevant samples for differential diagnosis in 274 
such acute presentations and indicates that in EV-D68 suspected cases respiratory 275 
specimens are the most appropriate for diagnostic testing and virological 276 
characterization.  277 
The rate of positivity in cases of acute respiratory disease presenting to primary care 278 
in England doubled from autumn/winter 2013-2014 to autumn/winter 2014-2015. 279 
Nonetheless this increase was not statistically significant and the number of cases and 280 
positivity rates were low. This suggests that the high number of severe cases observed 281 
in secondary care in the period post autumn 2014 is presumably explained by the 282 
change in case definition and enhanced case ascertainment. Similarly, in the 283 
Netherlands, a non-significant increase in the percentage of EV-D68 positives was 284 
observed from 2013 (0.3%) to 2014 (0.6%) among patients presenting to the GP [32]. 285 
In another similar study in Germany from 2014, a higher percentage (7.7%) of  EV-286 
D68 positive samples from outpatients presenting with ILI, and/or acute respiratory 287 
infection was reported [28]. Our primary care cases had similar distribution across all 288 
age groups, but in those in secondary care, age was skewed toward infants and young 289 
children (Figure 2). This could be related to the PHE guidance, suggesting considering 290 
EV-D68 as a possible cause of disease in children with severe respiratory symptoms. 291 
Or, taking into account similar results from other studies, it may demonstrate a 292 
different age profile of the EV-D68 cases presenting with severe symptoms in 293 
secondary care compared to the profile of the mild presentations in primary care. 294 
We characterized EV-D68 strains circulating in England since 2012 and up to winter 295 
2014-2015, among which we identified strains genetically similar to those detected in 296 
2014 in USA. These findings are consistent with similar results from Netherlands and 297 
Germany [15, 28]. These studies describe emergence of distinct genetic clusters, 298 
which reflects the continuous evolution of EV-D68 strains in circulation. 299 
With extensive genetic variation in the EV-D68 genome, continuous collection of 300 
genomic data by representative surveillance systems is required to ensure that PCR-301 
based detection methods are capable of detecting contemporary circulating viruses. 302 
Genotyping assays are generally based upon sequence analysis of the VP1 coding 303 
region, whilst primary detection assays usually target the 5′-untranslated region of the 304 
genome. With recognized sequence variation in both regions, complete genome 305 
sequences representing contemporary circulating viruses is essential in assuring 306 
performance of molecular diagnostic and characterization assays. 307 
However, to fully understand the clinical significance of detection of EV-D68 in 308 
patients, alongside genomic characterization, isolation of the virus, characterization by 309 
neutralization and measurement of virus-specific antibody titres is required. 310 
Integrating ‘classical’ virology approaches and molecular techniques will better 311 
establish links between infection and disease in patients, as well as provide valuable 312 
technical information for improving laboratory diagnostics, monitoring genetic drift in 313 
the virus genome which may result in degradation of PCR primer/probe-binding sites. 314 
Some molecular assays have been found to exhibit cross-reactivity between EV-D68 315 
and rhinovirus which can lead to false-positive results. Furthermore, with reports of 316 
other emerging and novel enterovirus types [1, 2, 33], it is important to continually 317 
enhance the virological, genomic and epidemiological understanding of these viruses 318 
by maintaining up-to-date diagnostic and reference methods, and monitoring the 319 
factors determining local and temporal differences in atypical disease outbreaks due to 320 
enteroviruses. 321 
The detection of EV-D68 worldwide in 2014-2015 may be the ‘tip-of-the-iceberg’ of 322 
circulation of EVD-68. EV-D68 is rarely associated with severe disease, which is 323 
probably why fewer cases have been detected by current surveillance systems that are 324 
designed to capture more severe (neurological) infections. In our study, detection of 325 
the virus in community and in hospitalized patients with respiratory disease suggest 326 
EV-D68, and perhaps other enteroviruses, are a more important cause of infection and 327 
potentially disease than captured by current surveillance systems. 328 
STRENGTHS AND LIMITATIONS 329 
Our study had some strengths and limitations. In terms of strengths, we were able to 330 
look at the EV-D68 epidemiology and virology in primary care before and after the 331 
signal in the US, using an identical surveillance system, which allowed the 332 
comparison between the two periods with no ascertainment bias. In terms of 333 
weaknesses, first, we could not compare the EV-D68 positivity rate in ESS with 334 
previous years given the change in case definitions in autumn 2014 following the PHE 335 
guidance mentioned before. Second, the RCGP RSC influenza sentinel surveillance 336 
samples are predominantly restricted to the winter months when influenza is 337 
circulating, considering the previously described EV-D68 seasonal pattern, majority 338 
of cases occurring in late summer and autumn [34, 35], we may have missed cases if 339 
they had occurred in summer or late spring. Furthermore, the representativeness of the 340 
RCGP RSC influenza sentinel surveillance is not ideal for an estimate of the real 341 
circulation of this virus in patients presenting to primary care, as the patients tested 342 
present with acute febrile respiratory illness, and during the 2014 outbreak in the US 343 
only 48% of the hospitalized cases presented with fever; additionally EV-D68 may be 344 
a more common cause of mild respiratory illness both in primary care and in the 345 
community among cases who self-manage without seeking healthcare intervention. 346 
Nonetheless, the RCGP RSC is a representative network, with only small differences 347 
with the national population and therefore the results of this study provide a useful 348 
baseline for future monitoring of the circulation of EV-D68 and its severity in 349 
England[17]. Finally, we did not sequence the whole genome which might contain 350 
virulence markers elsewhere. For example, changes in the 5′UTR and IRES have been 351 
proposed to associate with changes in translation initiation [36] and virulence [37, 38]. 352 
CONCLUSIONS 353 
In this study we detected EV-D68 in cases of severe acute respiratory illness and, less 354 
commonly, in neurological illness, particularly in children and those with underlying 355 
disease from autumn 2014 when enterovirus surveillance system was enhanced and 356 
respiratory sampling was included. We also provided evidence of EV-D68 in cases of 357 
ILI presenting in primary care before and after autumn 2014, with strains genetically 358 
similar to those detected in 2014 in the USA.  359 
EV-D68 should be considered as a possible cause of disease in patients presenting 360 
with severe acute respiratory infections and/or with unexplained neurological 361 
symptoms. Our findings emphasize the necessity of reinforcing enterovirus 362 
surveillance in England. We recommend the screening of respiratory samples for 363 
enterovirus, particularly EV-D68, from patients presenting with severe acute 364 
respiratory infections and/or with unexplained neurological symptoms, when all other 365 
respiratory virus screen are negative or if an indeterminate rhinovirus/enterovirus 366 
positive result was initially detected. The surveillance of enterovirus, specifically EV-367 
D68, in respiratory samples will help us to better understand the epidemiology of EV-368 
D68 and to inform surveillance and laboratory-testing guidance.  369 
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 TABLES AND FIGURES 
Table 1. Clinical presentation and severity of EV-D68 positive cases in secondary care in England, September 2014 to January 2015. 
Clinical Presentations-Severity (N=45) n % 
Respiratory symptoms (including one case with 
neurological symptoms) 
41 89 
Asthma or wheezing 13  33 (N=39) 
Immunocompromised or severe underlying diseases 
(all) 
21 46 
Admitted to hospital 37 82 
Respiratory presentations 34 75 
Intensive Care 12 27 
Neurological presentations  2 4 
Deaths 2 4 
 
Figure 1.  Distribution of EV-D68 cases detected in the Royal College of General Practitioners (RCGP) influenza sentinel surveillance system 
and in the Enterovirus Surveillance System (ESS) (including positives from before September 2014 and other later cases for whom clinical 
information is not available) by week of sample, England, September 2013 to March 2015. 
Figure 2. Number of EV-D68 cases by sex, age and surveillance system where detected, England September 2013- January 2015. ( (RCGP: 
Royal College of General Practitioners influenza sentinel surveillance system, (primary care.) EES: Enterovirus Surveillance System (secondary 
care))  
Figure 3. Phylogenetic analysis of partial VP1 sequences of EV-D68 covering the BC and DE loops of the VP1 region. The evolutionary history 
was inferred using the Neighbour-Joining method and the optimal tree with the sum of branch length = 0.95104738 is shown. The percentages of 
replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches (where 
>90%). The tree is drawn to scale. Analyses were conducted in MEGA6 [18]. (green)=ESS specimens; (blue)=RCGP specimens; =Cases 
associated with neurological illness; =Reference sequences 
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